問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1733Cases

2019-11-30 - 2022-05-19

Phase III

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Condition/Disease

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis

  • Test Drug

    Momelotinib Tablets；Danazol Capsules

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2020-02-01 - 2021-01-31

Phase I

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)

  • Condition/Disease

    Chronic hepatitis B virus (CHB) infection

  • Test Drug

    EDP 514

Participate Sites
10Sites

Recruiting3Sites

Terminated7Sites

2014-07-01 - 2023-10-25

Phase III

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated4Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2014-09-01 - 2019-11-30

Phase II

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablets

Participate Sites
5Sites

Terminated5Sites

2015-07-01 - 2020-12-31

Phase III

A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy ≥1 month to <4 years of age with partial-onset seizures

  • Condition/Disease

    partial-onset seizures

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

2015-05-01 - 2018-12-31

Phase II

A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTIs)

  • Condition/Disease

    Complicated urinary tract infections (cUTIs)

  • Test Drug

    Ceftazidime Avibactam powder for concentrate for solution for infusion 2000 mg / 500 mg

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2015-03-01 - 2019-04-30

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

  • Condition/Disease

    with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates

  • Test Drug

    SGI-110 for subcutaneous injection

Participate Sites
7Sites

Terminated5Sites

高志平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-11-01 - 2016-12-31

Phase II

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    GS-4774 Powder for Suspension for Injection

Participate Sites
3Sites

Terminated3Sites

2015-04-01 - 2018-12-31

Phase III

a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy

  • Condition/Disease

    idiopathic generalized epilepsy

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

周宜卿
China Medical University Hospital-Taipei

未分科

1 128 129 130 131 132 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB